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ABSTRACT 
Acute and Repeated Effects of Synthetic Cannabinoid Agonism and Cannabinoid Receptor 1 
Positive Allosteric Modulation 
Kristen R. Trexler 
Recent years have seen a rise in the diversity and use of synthetic cannabinoids. 
Currently, there is little known about the effects of specific synthetic cannabinoid compounds. 
As such, little research has been done evaluating the acute and chronic effects of synthetic 
cannabinoid administration or the development of tolerance and withdrawal. The present study 
aimed, in part, to evaluate the acute and repeated effect of a third-generation synthetic 
cannabinoid, AB-FUBINACA. Mice were treated with AB-FUBINACA (0.1-3 mg/kg, i.p.) or 
vehicle and were tested repeatedly in the tetrad battery of assays, which included tests of 
catalepsy, antinociception, hypothermia, and locomotor activity. A second group of mice was 
injected with AB-FUBINACA (3 mg/kg, s.c.) twice daily for 6 days and were tested daily in 
tetrad. On the 6th day, withdrawal was precipitated using the cannabinoid receptor antagonist 
rimonabant (3 mg/kg), and behavior was scored in the somatic signs of withdrawal tests. AB-
FUBINACA exhibited classic acute cannabinoid effects in the tetrad but showed a lack of 
tolerance and cross-tolerance to THC (50 mg/kg, i.p.). Further, precipitated withdrawal from 
AB-FUBINACA was of a much smaller magnitude than what is typical of other phyto- and 
synthetic cannabinoids. 
Another aspect of cannabinoid research that has been largely overlooked is the use of 
assays that are able to detect spontaneous (i.e., abstinence-induced) withdrawal. Previous 
research has demonstrated that spontaneous withdrawal can be detected with certain assays, like 
the somatic signs of withdrawal and tail suspension tests. To determine whether an anhedonia 
test would detect signs of spontaneous withdrawal, mice were trained to consume a sweetened 
condensed milk mixture over 9 days. During the final 6 days of training, mice were injected 
twice daily with THC (10 or 50 mg/kg, s.c.) or vehicle. On the 9th day, injections were stopped 
and mice were tested again at 12h and 36h abstinence. No changes were observed as a result of 
spontaneous withdrawal from THC.  
Despite recent increases in attention to cannabinoid use disorders, there remains a need 
for pharmacological interventions. ZCZ011 is a CB1 positive allosteric modulator that increases 
the effect of CB1 agonists bound at the orthosteric site. We hypothesized that ZCZ011 
significantly attenuates behavioral signs of cannabinoid withdrawal. Mice were administered ∆9-
THC (10 mg/kg, b.i.d., s.c.) or vehicle for six days, then withdrawal was precipitated using 
rimonabant (3 mg/kg, i.p.). As previously reported, ∆9-THC withdrawal induced paw tremors 
and head twitches. Acute ZCZ011 (≥10 mg/kg, i.p.) significantly attenuated paw tremors and 
head twitches. ZCZ011 (≥10 mg/kg, i.p.) was also administered to mice subjected to spontaneous 
THC withdrawal. ZCZ011 reduced spontaneous THC withdrawal-induced head twitches and 
paw tremors. An additional group of mice was injected with ZCZ011 (10 mg/kg, i.p.) or one of 
its enantiomers, ZCZ011 A or ZCZ011 B prior to precipitated THC withdrawal. Both ZCZ011 
10 mg/kg or either enantiomer alone attenuated paw tremors and head twitches. 
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1. Introduction
1.1 Endocannabinoid system 
Cannabinoids are molecules that (1) bind to and activate the cannabinoid (CB) receptors, 
or (2) share structural homology with known CB receptor ligands (Mechoulam & Parker, 2012). 
There are two cannabinoid G-protein coupled receptors, i.e., Cannabinoid receptor subtype 1 
(CB1) and Cannabinoid receptor subtype 2 (CB2), that affect intracellular signaling through the 
inhibition of adenylate cyclase (Howlett, 1985). CB1 is expressed primarily in the central 
nervous system, on GABAergic and glutamatergic neurons (Jacob et al., 2009; Steiner & 
Wotjak, 2008), whereas CB2 is expressed primarily in the periphery and also commonly 
expressed on glial cells and in the brainstem  (Finn, 2010). CB1 agonism is associated with 
psychoactive effects, including mild euphoria, relaxation, motor function disruption, and 
analgesia, typically reported during cannabis use. Conversely, CB2 is implicated in anti-
inflammatory and immunosuppressive effects that contribute to analgesia, which is a decrease in 
pain response (Lombard, Nagarkatti, & Nagarkatti, 2007). Both exogenous (i.e., externally 
administered) and endogenous (i.e., internally produced) cannabinoids bind to CB1 and CB2 
receptors with moderate to high affinity (Lombard et al., 2007; Singh et al., 2012). 
Activation of cannabinoid receptors leads to inhibition of adenylyl cyclase and the 
activation of mitogen-activated protein kinases, which ultimately cause inhibition of responses to 
stimuli that would normally depolarize the cell, and can decrease neurotransmitter release.  
(Freund, Katona, & Piomelli, 2003; Howlett, 2005; Mackie, 2008). Simultaneously, cannabinoid 
receptor activation closes N- and P/Q-type calcium (Ca2+) ion channels (Flores, Maldonado, & 
Berrendero, 2013; Steiner & Wotjak, 2008), and, due to freed Gβ/γ subunits and reduced cAMP, 
inward rectifying potassium (K+) channels are also activated (Deadwyler, Hampson, Mu, Whyte, 
& Childers, 1995; Mu, Zhuang, Kirby, Hampson, & Deadwyler, 1999). Together, these effects 
contribute to hyperpolarization of the presynaptic neuron, which inhibits neurotransmitter release 
and decreases excitatory post-synaptic potentials in the postsynaptic neuron.  
1.1.1 Phytocannabinoids 
Phytocannabinoids are compounds derived from the Cannabis plant. Over 60 different 
cannabinoids have been identified in cannabis, including the well-known and most tested Δ9-
tetrahydrocanabinol (THC) (Gaoni & Mechoulam, 1964). In addition to mild euphoria, THC can 
Synthetic Cannabinoid Agonism and Positive Allosteric Modulation - Trexler 
2 
cause cognitive deficits, such as memory loss and altered time perception (Mechoulam & Parker, 
2012; Morgan, Schafer, Freeman, & Curran, 2010).  
1.1.2 Endocannabinoids  
Endogenously produced cannabinoids (i.e., endocannabinoids) are produced in humans 
and are evolutionarily well preserved across vertebrates (Fisar, 2009). The two well-established 
endocannabinoids are 2-arachidonoyl glycerol (2-AG) and N-arachydonoylethanolamine, which 
is also known as anandamide for the Sanskrit word “ananda” meaning “bliss” (Devane et al., 
1992; Mechoulam et al., 1995). Endocannabinoid levels are comparable in most tissues except in 
the brain, where 2-AG is present in 100-fold higher levels than anandamide (Long et al., 2009). 
Both endocannabinoids bind to and activate CB1 and CB2 (Lu & MacKie, 2016; Mechoulam & 
Parker, 2012). Unlike neurotransmitters that are produced in the endoplasmic reticulum and 
stored in vesicles, endocannabinoids are synthesized de novo from lipid precursors, and rapidly 
released on demand.  
Endocannabinoid metabolism is tightly regulated by synthetic and catabolic enzymes. 
Although there is some controversy, a generally accepted synthetic pathway uses N-
Arachidonoyl-phosphatidylethanolamine specific phospholipase D (PLD) and phospholipase C 
(PLC) to convert N-Arachidonoyl-phosphatidylethanolamine (NArPE) into anandamide. 2-AG 
synthesis is more clearly delineated. 2-AG synthesis is more clearly delineated. Diacylglycerols 
(DAGs) are synthesized by diacylglycerol lipases α and β into 2-AG (Di Marzo, 2009; Flores, 
Maldonado, & Berrendero, 2013; Howlett, 2005). Anandamide is primarily catabolized by fatty 
acid amide hydrolase (FAAH) while 2-AG is primarily catabolized by monoacylglycerol lipase 
(MAGL), and the remaining ~15% is catabolized by the enzymes ABHD6, ABHD12, and 
cyclooxygenase (Blankman, Simon, & Cravatt, 2007; Cravatt et al., 1996; McKinney & Cravatt, 
2005). Chemical inhibition or genetic deletion of either FAAH or MAGL selectively increases 
anandamide or 2-AG levels, respectively. Enzymatic regulation of endocannabinoids by FAAH 
and MAGL is extremely efficient, effectively nullifying the exogenous administration of 
endocannabinoids. Thus, to study effects of the endocannabinoids in vivo, several compounds 
have been synthesized that act to selectively inhibit the activity of these catabolic enzymes, 
thereby indirectly increasing brain levels of anandamide or 2-AG.  
1.1.3 Synthetic cannabinoids 




The term “synthetic cannabinoid” technically refers to any lab-produced compound that 
affects CB1 or CB2 function and includes receptor agonists and antagonists, inhibitors of 
enzymes mentioned in the previous paragraph, as well as allosteric modulators, which are 
detailed in section 1.4 (Hess, Schoeder, Pillaiyar, Madea, & Müller, 2016). Colloquially, 
"synthetic cannabinoid" refers to a CB1 or CB2 agonist, and for the remainder of this document 
such compounds will be referred to as synthetic cannabinoids. These compounds were originally 
synthesized for research purposes, such as receptor/ligand interaction studies, or to selectively 
agonize one receptor without affecting the other (Banister, Moir, et al., 2015; Banister, Stuart, et 
al., 2015; Huffman et al., 2005). Once the chemical structures of synthetic cannabinoids were 
published, clandestine chemists hijacked the compounds and produced so-called “safe” 
alternatives to cannabis (Jarbe & Raghav, 2016).  
Though some individuals ingest powdered forms of synthetic cannabinoids, the most 
common route of administration is inhalation of smoked or vaporized plant material treated with 
one or more of the synthetic cannabinoids (Seely, Lapoint, Moran, & Fattore, 2012). Solutions of 
one or more synthetic cannabinoids, in a solvent, are often sprayed onto inert plant material, 
including blue and pink lotus, skull caps, or rose hips, but may also be applied to plant material 
containing psychoactive alkaloids (de Havenon, Chin, Thomas, & Afra, 2011; Dresen et al., 
2010; EMCDDA, 2009; Seely et al., 2012). Sold under the broad umbrella term “Spice,” these 
synthetic cannabinoid preparations are labeled "not for human consumption" to avoid regulation 
by the Food and Drug Administration (Brents, Zimmerman, Saffell, Prather, & Fantegrossi, 
2013), despite their true intended use. 
Synthetic cannabinoids are broadly categorized into 7 families, based on chemical 
structure: cyclohexyl-substituted phenols (e.g., CP 47,497), naphtholindoles (e.g., AM-2201, 
JWH-018), benzoylindoles (e.g., 6 APB), tetramethylcyclopropylindoles (e.g.,UR-144, XLR 11), 
adamantoylindoles (e.g., AKB48), indazole carboxamides (e.g.,AB-FUBINACA, AB-PINACA), 
and quinolinyl esters (e.g., PB22) (Canazza et al., 2016; Ford, Tai, Fantegrossi, & Prather, 2017; 
Hess et al., 2016). Though their structures differ, many synthetic cannabinoids act as full 
agonists at CB1, and in some cases CB2 (Fantegrossi, Moran, Radominska-pandya, & Prather, 
2014; Ford et al., 2017; Hess et al., 2016). Whereas THC is a partial agonist of CB1 and CB2, 
synthetic cannabinoids often have a relatively lower Ki value, indicating higher binding affinity, 
and thus synthetic cannabinoids induce similar cannabimimetic effects to THC, but at relatively 




lower doses (Hess et al., 2016; Wiley et al., 2015). In the “tetrad” battery of cannabinoid 
behavioral and physiological effects, both first generation (e.g., JWH-018, CP55,940) and later 
generation (e.g., AB-FUBINACA, AB-CHMINACA) synthetic cannabinoids induce catalepsy, 
antinociception, and hypothermia in mice (Paronis, Nikas, Shukla, & Makriyannis, 2012; Wiley 
et al., 2015). See Table 1 for examples of generational structure differences. Unlike THC, which 
has dose-dependent sedative effects in rodents, synthetic cannabinoids have inconsistent effects 
on locomotor activity. For instance, acute high and low dose AB-FUBINACA administration 
decreased locomotor activity in rats in one study (Kevin et al., 2017), but only high doses 
induced immobility in two other studies that used mice (Gatch & Forster, 2015; Schreiber et al., 
2018).  
Table 1. Structures of representative synthetic cannabinoids by generation. 
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While there are many issues associated with human synthetic cannabinoid use, one of the 
primary concerns is their ever-increasing diversity and the lack of regulation surrounding their 
creation and distribution. As of 2015, 160 independent synthetic cannabinoid compounds have 
been identified in samples obtained from shops and over the internet (EMCDDA 2016). 
Research into synthetic cannabinoids has expanded from exploring primarily pharmacological 
and behavioral outcomes to include studies of routes of administration, metabolism, and human 
patterns of synthetic cannabinoid use (Banister, Moir, et al., 2015; Chase et al., 2016; Fantegrossi 
et al., 2014; Lefever et al., 2017; Su, Seely, Moran, & Hoffman, 2015; Wiebelhaus et al., 2012). 
Though many synthetic cannabinoids are assumed to have abuse potential, little work has 
evaluated the development of tolerance and withdrawal of the newest families of cannabinoids. 
Further, much of the research done using synthetic cannabinoids rely primarily on physiological 
and gross behavioral outcomes (Banister, Moir, et al., 2015; Gatch & Forster, 2015; Kevin et al., 
2017), with little attention given to dependence and withdrawal effects. 
 
1.1.3.1 AB-FUBINACA 
AB-FUBINACA is a member of the indazole carboxamide family of synthetic 
cannabinoids that also includes AB-CHMINACA and AB-PINACA, both of which have been 
linked to deaths in the United States (Trecki, Gerona, & Schwartz, 2015). AMB-FUBINACA 
was responsible for a recent series of overdoses in Connecticut. In August of 2018 at least 71 
people presented to emergency services with loss of consciousness, vomiting and nausea, and 
lethargy but displayed no physiological abnormalities (https://www.cbsnews.com/news/new-
haven-overdoses-connecticut-new-haven-green-k2-synthetic-marijuana). This absence of AMB-
FUBINACA induced physiological effects is unusual, as most synthetic cannabinoids induce 
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tachycardia, bradycardia, and/or elevated blood pressure in humans (Chinnadurai, Shrestha, & 
Ayinla, 2016; Davidson et al., 2017; Mir, Obafemi, Young, & Kane, 2011). In contrast, AB-
FUBINACA induces bradycardia in rats (Banister, Moir, et al., 2015). This interspecific 
difference is likely due to differences in dosing, or perhaps metabolism. 
AB-FUBINACA is one of the better characterized of the new generation of indazole 
carboxamide synthetic cannabinoids. AB-FUBINACA induces hypothermia and decreases 
locomotor activity in both mice (Schreiber et al., 2018) and rats (Banister, Moir, et al., 2015; 
Kevin et al., 2017) and does not affect nociception in mice (Schreiber et al., 2018) although the 
lack of antinociception has not been probed in rats. It is somewhat surprising that no data are 
available on AB-FUBINACA effects on catalepsy, given that catalepsy is a classic cannabinoid 
effect (Wiley et al., 2015). In a drug discrimination task, AB-FUBINACA fully substitutes for 
THC, although it also depresses response rate, with incomplete cross-tolerance between the two 
cannabinoids (Gatch & Forster, 2015).  
Cannabinoids have well-established effects on emotion in people, as well as in 
experimental animal models. AB-FUBINACA is similar to THC in that it elicits anxiolytic-like 
effects in low doses in the elevated plus maze, but it diverges from THC by producing 
anxiogenic-like effects in high doses, in mice (Schreiber et al., 2018). In addition, AB-
FUBINACA decreases struggling in the forced swim test at a low dose (Schreiber et al., 2018), 
which is generally indicative of a depressive-like effect, but increases struggling at a high dose, 
which is generally interpreted as anti-depressive-like or manic effect.  
1.2 Human synthetic cannabinoid use 
As mentioned in section 1.1.3, synthetic cannabinoids were initially developed for 
therapeutic purposes (Huffman et al., 2005) although many have been hijacked for recreational 
use. It is because of this unplanned human use and unpredictable negative effects that synthetic 
cannabinoids have gained such recent attention. Yet, it is important to keep in mind that, some 
synthetic cannabinoids have proven effective in attenuating disease states. For instance, JWH-
133, a selective CB2 agonist, and WIN55,212-2, a nonselective CB1 and CB2 agonist, both 
inhibit breast tumor growth and metastasis in vitro and in vivo (Olea-Herrero, Vara, Malagarie-
Cazenave, & Díaz-Laviada, 2009; Qamri et al., 2009). The therapeutic use of synthetic 
cannabinoids has been severely limited, however, by the presence of side effects in preclinical 
models, including abuse potential and seizure (Cooper, 2016; de Havenon et al., 2011; Schaefer 




et al., 2013). Thus it is not surprising that, as of October 2018, 1,478 poison control calls 
regarding synthetic cannabinoid use have been reported (“American Assoication of Poison 
Control Centers: Synthetic Cannabinoids,” 2018). The following sections will focus on the acute 
and chronic effects of synthetic cannabinoid administration, with an emphasis on the effects in 
humans, because much of the research and literature on these drugs is effectively playing catch-
up with clinical reports of what is being used.  
1.2.1 Acute use 
Recreational use of synthetic cannabinoids has increased dramatically in recent years, and 
with increased use, there has been a concomitant increase in emergency department visits. Few 
assays currently detect synthetic cannabinoids in blood or urine (Islam et al., 2018; Muehlethaler, 
Leona, & Lombardi, 2016; Sobolevsky, Prasolov, & Rodchenkov, 2010), an issue that is 
compounded by the ever-changing synthetic cannabinoids used in spice compounds. Thus, it has 
been difficult to track exactly which synthetic cannabinoid(s) caused a given adverse health 
episode. Even determining the dose ingested can be difficult, because the plant materials often 
have “hot spots,” as a result of uneven distribution, and high inter- and intra-batch variability in 
quality and dose (Frinculescu, Lyall, Ramsey, & Miserez, 2017; Hudson & Ramsey, 2011; 
Marshell et al., 2014; van Amsterdam, Brunt, & van den Brink, 2015). Moreover, of the cases 
where the compounds involved are known, there is often more than one compound present 
(Musshoff et al., 2014). Thus, when evaluating the health outcomes of synthetic cannabinoids, 
they are often grouped together, irrespective of drug family. Regardless of this caveat, synthetic 
cannabinoids clearly differ from cannabis in their effects.  
 In humans, acute synthetic cannabinoid use can cause symptoms including: agitation, 
anxiety, hallucinations, tachycardia, bradycardia, hypotension, diaphoresis, diarrhea, vomiting, 
myocardia ischemia, and rhabdomyolysis (Benford & Caplan, 2011; Besli, Ikiz, Yildirim, & 
Saltik, 2015; Bhanushali, Jain, Fatima, Leisch, & Thornley-Brown, 2013; Clark, Georgekutty, & 
Berul, 2015; Durand, Delgado, Parra-Pellot, & Nichols-Vinueza, 2015). Several deaths and 
serious injuries have been reported following acute synthetic cannabinoid use, including self-
mutilation and several suicides, most of which have been attributed to hallucinations (Gay, 2010; 
Meijer, Russo, & Adhvaryu, 2014; Patton et al., 2013; Thomas, Kloner, & Rezkalla, 2014; 
Trecki et al., 2015). Psychosis induced by synthetic cannabinoid use is so common that some 
researchers have proposed referring to it as “spiceophrenia” (Papanti et al., 2013). In a study that 




retroactively reviewed emergency room presentations from 16 different locations across Europe, 
approximately 15% patients presenting with psychosis reported using synthetic cannabinoid 
products (Vallersnes et al., 2016). However, these self-report measures are hampered by the 
inability of users to identify which specific drug(s) they may have ingested (again, spice products 
do not list ingredients), as well as polydrug use.  
The acute hallucinogenic effects of synthetic cannabinoids may be explained by their 
indirect effects on dopamine and serotonin, via GABA and glutamate modulation. For example, 
JWH-018 increases dopamine in the nucleus accumbens in a manner similar to schizophrenia, 
however, this effect is likely achieved by modulating glutamate and GABA, rather than acting 
directly on dopamine (El Khoury, Gorgievski, Moutsimilli, Giros, & Tzavara, 2012; Fantegrossi, 
Wilson, & Berquist, 2018). Additionally, synthetic cannabinoids can increase the formation of 
5HT2A-DA2 heterodimers in the prefrontal cortex in rats, which has been implicated as a possible 
mechanism for the positive symptoms of schizophrenia (Franklin & Carrasco, 2012). Thus, the 
presence of psychosis and hallucinations may be explained by synthetic cannabinoid interactions 
with dopamine and serotonin.  
 A particularly dangerous, yet poorly understood, side effect of acute synthetic 
cannabinoid use is seizure. Seizures induced by synthetic cannabinoid use may occur 
immediately (i.e., within minutes of use) or after a delay of several hours or even days (de 
Havenon et al., 2011; Schaefer et al., 2013). Although the physiological mechanism(s) are 
unknown, it is hypothesized that off-target effects, lack of quality control, toxicity (absence of 
mitigating phytocannabinoids and endocannabinoids), ligand bias, or active 
metabolites/degradants are likely contributing factors (Chimalakonda et al., 2012; Pertwee, 
2009). Further complicating mechanistic studies, the metabolites of many synthetic cannabinoids 
are active and bind to and activate CB receptors at similar affinities to the parent compound 
(Erratico et al., 2015; Fantegrossi et al., 2014). This is in contrast to THC, which has only one 
psychoactive metabolite, 11-OH-THC (Huestis, 2007; Matsuda, Lolait, Brownstein, Young, & 
Bonner, 1990).    
1.2.2 Chronic use  
Little is known about the effects of chronic synthetic cannabinoid administration. One 
case report indicates that repeated synthetic cannabinoid use may lead to relatively long-term 
psychosis (Durand et al., 2015). It is plausible that 5HT2A receptors mediate the psychogenic 




effects of synthetic cannabinoids, because their upregulation in schizophrenia, and following 
repeated synthetic cannabinoid use, is mediated through CB1 activation (Fantegrossi et al., 2018). 
A more common effect of chronic drug use is dependence. There is evidence, in both preclinical 
models and from case reports, that repeated use of synthetic cannabinoids induces tolerance and 
dependence, as evidenced by withdrawal following cessation of use (Aceto, Scates, & Martin, 
2001; Nacca et al., 2013; Sampson, Bedy, & Carlisle, 2015; Trexler et al., 2018). The potential 
for dependence and withdrawal presents a major problem. Currently, cannabis is the most 
commonly used federally illicit substance for which individuals seek treatment, and there are few 
effective options for its treatment (Substance Use and Mental Health Services Administration, 
2015).  
1.3 Cannabis Use Disorder 
In addition to the acute health risks of cannabis use, such as increased risk of vehicular 
accidents (Hartman & Huestis, 2013), chronic use induces varying degrees of dependence. In 
clinical populations, cannabis dependence, also referred to as Cannabis Use Disorder (CUD), is 
now routinely tracked by health care professionals. Although only 2-6% of users are estimated to 
experience some level of CUD, the overall number of people with some level of CUD is 
expected to grow as cannabis becomes more widely available (Hasin et al., 2016). CUD is most 
often characterized by the presence of withdrawal symptoms following cessation of drug use.  
Withdrawal symptoms of CUD vary across individuals, but typically include anxiety, 
depression, sleep disturbances, and can include somatic symptoms, including gastric 
disturbances and headache (American Psychiatric Association, 2013). The presence of 
cannabinoid withdrawal symptoms can lead to relapse after cessation (Budney, Vandrey, 
Hughes, Thostenson, & Bursac, 2008; Haney et al., 2013). Cognitive behavioral therapies have 
seen modest short-term success in reducing CUD, with only 19-29% of individuals maintaining 
abstinence at a 12-month follow up (Budney, Vandrey, Hughes, Moore, & Bahrenburg, 2007; 
Ramesh & Haney, 2015). Unlike other commonly abused drugs, like opioids or nicotine, there 
are currently no FDA approved pharmacological therapies to relieve cannabinoid withdrawal 
symptoms (Allsop, Lintzeris, Copeland, Dunlop, & McGregor, 2015; Mason, Mustafa, Filbey, 
Brown, & Mason, 2016).  




Presently, pharmacological treatments for CUD have focused on its symptoms (e.g., 
anxiety and depression) or oral administration of THC. For instance, anti-depressant and anti-
anxiety medications that act on noradrenergic, serotonergic and GABAergic targets have been 
used to treat specific aspects of withdrawal, but are not effective in attenuating withdrawal as a 
whole (Brezing & Levin, 2017). Several studies have attempted to treat cannabis withdrawal by 
administering THC or dronabinol (i.e., synthetically produced Δ9-THC, brand name Marinol), 
which were unsuccessful at preventing relapse, but did relieve depression associated with 
withdrawal (Haney et al., 2008, 2004). Combinations of cannabinoid and non-cannabinoid 
therapies have been effective in attenuating some symptoms of withdrawal, however,  they 
enhance other symptoms, like withdrawal-induced anorexia and sedation (Haney et al., 2008; 
Levin et al., 2016). 
The growing popularity of synthetic cannabinoids, coupled with their unpredictably 
psychogenic effects, raises concerns about the potential for dependence. Many individuals 
initiate synthetic cannabinoid use under the age of 25 and have a previous history of using 
cannabis (Monte et al., 2017; Morean, Kong, Camenga, Cavallo, & Krishnan-Sarin, 2015). 
Individuals who initiate cannabis use earlier in life are more likely to develop CUD (Budney et 
al., 2007). Thus, while the long-term effects of synthetic cannabinoid use are still largely 
unknown, case reports indicate that the withdrawal syndrome is similar to withdrawal from 
cannabis, but may be more severe, in one case producing multiple seizures on multiple cessation 
attempts (Nacca et al., 2013; Sampson et al., 2015). The growing, world-wide use of synthetic 
cannabinoids highlights the need for effective pharmacological interventions for cannabinoid 
dependence. 
1.4 Positive CB1 allosteric modulation  
An exciting, recently developed research tool that has shown promise in preclinical 
models is CB receptor allosteric modulation. Positive allosteric modulators (PAMs) bind to the 
allosteric (i.e., non-orthosteric) sites of receptors, and act to increase the efficacy and/or affinity 
of orthosteric ligands (Kenakin, 2013). Because they bind to allosteric site(s), rather than the 
orthosteric site, CB1 PAMs represent an alternative approach for treating cannabinoid-related 
disorders (Burford, Traynor, & Alt, 2015; Ross, 2007; Figure 1). For example, the synthetic CB1 
PAM, GAT211, is antinociceptive in acute mechanical and neuropathic pain models, but does 




not elicit cannabimimetic effects in mice (Slivicki et al., 2017). Our own data indicate that the 
CB1 PAM ZCZ011 attenuates THC withdrawal, without inducing cannabimimetic side effects, 
by increasing efficacy or affinity of endocannabinoids (Trexler, Eckard, & Kinsey, 2019).   
The present studies evaluated the behavioral effects of acute and repeated administration 
of a new generation of synthetic cannabinoid, AB-FUBINACA, and have evaluated both 
ZCZ011 and its enantiomers as therapeutic targets for THC withdrawal. The goals of these 
studies were to: 1. evaluate acute and chronic effects of AB-FUBINACA in the classic 
cannabinoid tetrad battery; 2. Evaluate the utility of anhedonia as a measure of spontaneous THC 
withdrawal; and 3. determine the utility of the positive allosteric modulator ZCZ011 and its 
enantiomers in attenuating THC withdrawal.  
2. Methods 
2.1 Animals 
Adult male and female C57BL/6J mice (N=589) (The Jackson Laboratory; Bar Harbor, ME) 
were group housed (4-5 per cage) in Polysulfone plastic cages with food and water available ad 
libitum. Mice were housed in a single temperature (20-22°C) and humidity (50 ± 5%) controlled 
room. Mice were kept on a 12:12 h light/dark cycle and were randomly assigned to each 
treatment group, such that each cage contained mice from at least two different treatment groups 




(e.g., no cage contained only AB-FUBINACA-treated mice). Experiments that used male and 
female mice were stratified by sex before random assignment. All experiments were carried out 
by trained technicians who were blinded to treatment conditions. The Animal Care and Use 
Committee at West Virginia University approved all experimental protocols prior to the start of 
any experimental manipulation. 
 
2.2 Drugs 
 The cannabinoid receptor agonists AB-FUBINACA, ∆9-THC, JWH-018, and the 
selective CB1 receptor antagonist rimonabant (SR141716A) were generously provided by the 
National Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD). ZCZ011 
was purchased from Axon Medchem (Reston, VA) or provided by a collaborator (Dai Lu, 
Texas A&M College of Pharmacy) who also provided the ZCZ011 racemates. All drugs were 
dissolved in a vehicle composed of 5% ethanol, 5% Kolliphor EL (Sigma-Aldrich, St. Louis, 
MO), and 90% normal saline (Kinsey & Cole, 2013). All solutions were warmed to room 
temperature before administration at a volume of 10 µl/g body mass.  
2.2.1 Precipitated withdrawal paradigm: Mice were weighed daily and injected subcutaneously 
(s.c.) with AB-FUBINACA (1 or 3 mg/kg) or vehicle every 12 h for 6 days, as described 
previously (Falenski et al., 2010; Schlosburg et al., 2009; Trexler et al., 2018). On the sixth day, 
all mice received a final injection of AB-FUBINACA or vehicle. After 30 min, mice received an 
intraperitoneal (i.p.) injection of rimonabant (3 mg/kg) (Lichtman, Fisher, & Martin, 2001; 
Trexler et al., 2018) to precipitate withdrawal. Control mice received a vehicle injection on test 
day.  
2.2.2 Spontaneous withdrawal paradigm: Mice were weighed daily and injected subcutaneously 
(s.c.) with either THC (10 mg/kg) or vehicle every 12 h for 6 days. Behavioral assessment in the 
anhedonia assay was conducted 36 h after the final injection. 
 
2.3 Behavioral Assessments 
2.3.1 Tetrad: The “Billy Martin tetrad” is a well characterized battery of four assays used to 
evaluate the effects of cannabinoid agonists (Kinsey & Cole, 2013; Lichtman et al., 2001; 
Schlosburg et al., 2010). It consists of: catalepsy, antinociception, core body temperature, and 
locomotor assessment. Catalepsy was assessed by gently laying the forepaws of individual mice 




over bar 3 cm above the benchtop. Total latency to move one or both forepaws off the bar was 
recorded, with a maximum cutoff of 60 s (Long et al., 2009). Antinociception was measured via 
immersing the distal tip of the tail (i.e., the last 1 cm) into a 56°C water bath (Falenski et al., 
2010). Latency to remove the tail from the water was recorded, with a maximum cutoff of 10 s. 
Hypothermia was assessed by taking rectal temperature using a micro probe thermocouple 
thermometer designed for use with mice (BAT-12, Physitemp Instruments Inc., Clifton, NJ, 
USA). Spontaneous locomotor activity was measured by placing individual mice into an empty 
test chamber (30 cm W x 40 cm L x 16 cm H) fitted with an overhead video camera, and 
locomotor activity was scored using ANY-maze video tracking software (Stoetling, Wool Dale, 
IL) for 5 min. In cases where mice were repeatedly tested a modified tetrad was used which 
includes only catalepsy, antinociception and hypothermia assessments, as mice habituate to 
locomotor testing. 
 
2.3.2 Somatic signs testing: Somatic signs of withdrawal were measured as described previously 
(Trexler et al., 2018). Each mouse was placed into an empty, plastic test chamber (20 cm W x 20 
cm L x 15 cm H) inside a sound-attenuating chamber outfitted with a fan and white LED 
lighting. The apparatus had three clear sides and one mirrored side that faced a video camera to 
allow for observation of behavior when the mouse faced away from the camera.  
 Mice were habituated to the test apparatus following final AB-FUBINACA or vehicle 
injection for 30 min and were then removed and injected with rimonabant or vehicle, as 
previously reported (Schlosburg et al., 2009). The boxes were cleaned between subjects using a 
paper towel moistened with distilled water. Each mouse was then be placed back into the test 
chambers and video recorded for 60 min.  
 Video files were deidentified and scored by a trained observer. A subset of videos were 
scored by a second observer to ensure inter-rater reliability (r2= .97). The dependent variables 
were incidences of paw tremors and head twitches (i.e., an incidence was scored for ‘paw 
tremor’ when the behavior was observed, not for each individual motion). Incidences were 
considered separate when either (1) another behavior occurred between the incidences, or (2) 
there was at least 1 s between incidences (Schlosburg et al., 2009).  
 




2.3.3 Marble Burying Test: Marble burying was measured as previously described (Broekkamp, 
Rijk, Joly-gelouin, & Lloyd, 1986; Trexler et al., 2018), with minor changes. Plastic test 
chambers (30 cm W x 40 cm L x 16 cm H) filled with Teklad Aspen Sani-Chip (7090A; Envigo, 
Indianapolis, IN) wood bedding (5 cm deep) were placed inside sound-attenuating chambers 
outfitted with a fan and LED lighting. A 5 x 5 array of 25 clear glass marbles was laid across the 
top of the leveled bedding. Each mouse was placed into the chamber and allowed to freely 
explore for 20 min. At the end of the test, each mouse was quickly and carefully removed and the 
number of unburied marbles (≥1/3 of the surface showing) was recorded then subtracted from the 
25 total marbles. Marbles were counted by a trained individual. Locomotor activity was 
simultaneously recorded for the duration of the test by a camera mounted on the top of the test 
chamber. The video data was analyzed in real time using ANY-maze (Stoetling, Wool Dale, IL) 
video tracking software.  
 
2.3.4 Tail Suspension Test: The tail suspension test was run as previously described (Kinsey, 
Bailey, Sheridan, Padgett, & Avitsur, 2007; Steru, Chermat, Thierry, & Siman, 1985). Mice were 
suspended by the tail with adhesive tape from a horizontal bar placed approximately 40 cm 
above the benchtop and video recorded for 6 min. The total time the mice actively struggled was 
hand-scored using ANY-maze (Stoetling, Wool Dale, IL) video tracking software. Active 
struggling was operationally defined as one or more legs kicking repeatedly within one second, 
or arching of the spine, but not head movement.  
 
2.3.5 Light/Dark Box: The light/dark box test was conducted as described previously (Crawley & 
Goodwin, 1980). The apparatus consisted of two connected Plexiglas chambers, with a small 
passage hole at floor level. The larger chamber (30 cm W x 40 cm L x 30 cm H) was open and 
brightly lit by an overhead lamp, and the smaller chamber (30 cm W x 20 cm L x 30 cm H) was 
covered and constructed using dark red Plexiglas. Each apparatus was placed within a sound 
attenuating chamber outfitted with a fan and LED lighting. In addition, an infrared LED array 
(IR3, C&M Vision Technologies Inc, Houston, TX), along with a video camera (Logitech HD 
Pro Webcam C920) with the infrared filer removed, were used to visualize the mice. Each mouse 
was placed in the brightly lit area of the apparatus and allowed to freely explore for 5 min. 
Locomotor activity was analyzed in real time using ANY-maze software (Stoetling, Wool Dale, 




IL). The dependent variables are total time spent in the dark box, latency to enter the dark box, 
time immobile, and total distance traveled. 
 
2.3.6 Open field: The open field test was conducted as previously described (Bailey, Kinsey, 
Padgett, Sheridan, & Leblebicioglu, 2009). The apparatus consisted of a (40 cm W x 40 cm L x 
30 cm H) box made of black Plexiglas with a white floor. Testing was carried out in individual 
sound attenuating chambers fitted with LED lighting, a fan, and an overhead video camera. Mice 
were individually placed into each apparatus and allowed to explore for 10 min. The field was 
divided evenly into 36 squares which were then divided into two zones: the perimeter, which was 
the space within 6 cm of the wall, and the center, which was the remaining 28 x 28 cm area not 
adjacent to the walls (Kinsey et al., 2007). Time spent in the center of the apparatus, distance 
traveled, and time immobile were quantified in real time using ANY-maze software (Stoetling, 












2.3.7 Novelty-induced hypophagia: Novelty-induced hypophagia testing was conducted as 
previously described (Gamble-George et al., 2013), with minor changes. Mice were single 
housed at least 7 days prior to training. Mice were trained to consume a mixture of 1:3 parts 
sweetened condensed milk and distilled water under dim light from sipper tubes placed in the 
home cage. Training took place for 3 days (Figure 2), or until each mouse achieved a threshold 
of consuming at approximately 1ml of the sweetened condensed milk mixture, whichever was 
longer.  
Figure 2. Time line for novelty-induced hypophagia. 




On the first test day, mice were randomly assigned and tested for 30 min in either the 
home cage under dim light, or an aversive condition. The dim light condition was the same as the 
training condition (i.e., 2 lux red light in home cage). The aversive condition consisted of a 
novel, empty (i.e., no bedding) cage placed on a white floor and brightly lit (1348 lux). On the 
second test day, mice were tested in the counterbalanced condition. Drug treatments were 
constant across test days. The following day, each mouse was returned to the training condition 
and tested again, but without drug. The dependent variable was the volume of sweetened 
condensed milk consumed. The volume was quantified by subtracting the post-test mass of the 
bottle from the pre-test mass. A drip control (i.e., a bottle placed in a dummy cage that was not 
used for testing) was included with each test group to account to for leakage. The data presented 
represent the total volume consumed, controlled for the drip control for that day.   
(𝑚𝑎𝑠𝑠𝑝𝑟𝑒 − 𝑚𝑎𝑠𝑠𝑝𝑜𝑠𝑡)𝑡𝑒𝑠𝑡 − (𝑚𝑎𝑠𝑠𝑝𝑟𝑒 − 𝑚𝑎𝑠𝑠𝑝𝑜𝑠𝑡)𝑑𝑟𝑖𝑝 𝑐𝑜𝑛𝑡𝑟𝑜𝑙  
 
2.3.8 Anhedonia: Anhedonia is a reduced response to a reinforcer, often modeled as decreased 
drinking of a highly palatable substance. Training was identical to the training phase of novelty-
induced hypophagia. When used to evaluate withdrawal, mice were trained to consume the 
sweetened condensed milk mixture for 3 days prior to drug administration and continued daily 
training through the 6-day drug administration phase. On test day, each mouse was habituated to 
the dim room 35 h following final drug injection and tested 1 h later. Volume of sweetened 
condensed milk consumed was quantified, as in the novelty-induced hypophagia test. 
 
2.4 Statistical analyses 
For experiment 1, data were analyzed using a repeated measures analysis of variance (ANOVA) 
with dose as the within subjects variable. For experiment 2a, precipitated withdrawal data were 
analyzed using a one-way ANOVA. For the spontaneous THC withdrawal experiment, t tests 
were used to evaluate differences at training day 3, dosing days and 36 h abstinence. For 
experiment 3a, one-way ANOVAs were used, with the exception of novelty-induced hypophagia 
data, which were analyzed using a mixed design with day as the within subjects variable and 
drug treatment as the between subjects variable. For experiment 3b, marble burying and tail 
suspension data were analyzed using 2x3 ANOVAs. All other studies in experiment 3b were 
analyzed using one-way ANOVAs. Main or interaction effects were followed by Dunnet (e.g., 




for dose-response curves, comparing to vehicle treatment) or Bonferonni post hoc tests, as 
appropriate. Differences were considered statistically significant if p < 0.05. 
3. Results 
The experiments in this study were designed to evaluate both acute and chronic effects of 
AB-FUBINACA, withdrawal from THC and attenuation of withdrawal from THC. Experiment 1 
evaluated acute and chronic AB-FUBINACA in the tetrad battery of tests. Experiment 2 
evaluated precipitated withdrawal from AB-FUBINACA. Finally, Experiment 3 evaluated the 
effects of acute ZCZ011, a CB1 positive allosteric modulator, and both of its enantiomers, and 
their ability attenuate the somatic signs of THC withdrawal. 
 
3.1 Experiment 1: AB-FUBINACA induces classic cannabinoid effects. To evaluate the acute 
effects of AB-FUBINACA, male and female mice were injected with AB-FUBINACA (0.1, 1, 2, 
or 3 mg/kg) or vehicle 30 min prior to testing. AB-FUBINACA (3 mg/kg) increased latency in 
both catalepsy [F(4,32)=6.6,p<.05; Fig. 3A] and tail immersion [F(3,35)=6.9,p<.05; Fig. 3B] 
tests. Mice treated with AB-FUBINACA (2 or 3 mg/kg) had decreased body temperature 
[F(34,35)=24.9,p<.05; Fig. 3C] and increased time immobile [F(4,35)=11.4,p<.05; Fig. 3D]. The 
antinociceptive (30 min), cataleptic (1 h), and hypothermic (2 h) effects of AB-FUBINACA 
abated quickly [Fig.3E-G], as compared with the same effects of THC (50 mg/kg). 
 In a separate experiment, male and female mice were dosed twice daily with AB-
FUBINACA (3 mg/kg) for 5 days and were tested daily in tetrad, to determine the degree to 
which AB-FUBINACA tolerance develops. Mice repeatedly administered AB-FUBINACA 
maintained increased latency in catalepsy [Main effect drug F(1,70)=31.8,p<.05;Fig. 4A] 
antinociception [Main effect drug F(1,70)=15.3,p<.05;Fig. 4B], and hypothermia despite 5 days 
of treatment [Main effect drug F(1,70)= 121.5,p<.05;Fig. 4C]. Similarly, when challenged with 
THC (50 mg/kg), mice treated with AB-FUBINACA for 5 days did not exhibit cross tolerance in 
catalepsy [p=.48; Fig. 4D], tail immersion [p=.87;Fig. 4E], or body temperature [p=.27;Fig. 4F]. 
 In the final experiment, male and female mice were injected twice daily with AB-
FUBINACA (1 or 3 mg/kg) for 5 days. On the 6th day, mice were injected with AB-FUBINACA 
and were injected with rimonabant 30 min later and were immediately tested in somatic signs of 
withdrawal. When rimonabant was administered, AB-FUBINACA (1 mg/kg) treated mice 
exhibited increased paw tremors [t(18)=3.8,p<.05;Fig. 4G] and head twitches 




[t(18)=3.0,p<.05;Fig.4H] compared to vehicle treated mice. Similarly, AB-FUBINACA (3 
mg/kg) withdrawal increased both paw tremors [F(2,20)=9.7, p<.05;Fig.4I] and head twitches 
[F(2,20)=4.3, p<.05;Fig.4J]. It is important to note that the rimonabant-precipitated somatic 
signs of withdrawal from AB-FUBINACA are of a smaller magnitude than those elicited by 
THC (10 or 50 mg/kg) or JWH-018 (1 mg/kg) withdrawal (Trexler et al., 2018). 
 
3.2 Experiment 2: Spontaneous THC withdrawal does not affect feeding. Because gastric issues 
are a commonly reported somatic sign of cannabinoid withdrawal, mice were trained to drink a 
sweetened condensed milk mixture and were treated twice daily for 6 days with either JWH-018 
(1 mg/kg) or vehicle. Withdrawal was precipitated with rimonabant (3 mg/kg). Acute JWH-018 
depressed drinking [Main effect of JWH-018 F(1,28)=279.3,p<.05; Fig. 5A], which returned to 
baseline levels by day 5 [p=.54], indicating tolerance had developed. Rimonabant, per se, 
significantly decreased feeding in both JWH-018 and vehicle treated mice Main effect of 
rimonabant F(1,28)=95.1, p<.05]. Thus, the spontaneous THC (10 or 50 mg/kg) withdrawal 
model was used next. Both THC (10 mg/kg) and vehicle groups consumed the same baseline 
(training day 3)volume of milk [p=.53; Fig. 5B] and THC-treated (10 mg/kg) mice returned to 
baseline consumption levels before testing [p=.19], indicating that THC tolerance developed. 
Mice were tested 12 and 36 h after the final THC (10 mg/kg) or vehicle injection. Both THC (10 
mg/kg) and vehicle treated mice consumed the same amount on test day [p=.16], indicating that 
spontaneous THC has no effect on drinking.  
Mice in both the THC and vehicle treated groups showed decreased in consumption 
following the injection of the first day of dosing. It is likely that this decrease was due to the 
stress of being injected. In a follow up experiment, the same experimental design was used, 
however, mice were injected with either vehicle or THC (50 mg/kg) twice daily. Mice were 
habituated to injections during training and vehicle-treated mice did not exhibit the same 
decrease in drinking on the first day of dosing. Again, THC treatment caused a decrease in 
drinking initially [t(6)=6.2, p<.05; Fig. 5C], and again, consumption returned to baseline by the 
5th day of dosing [p=.61]. As with THC (10 mg/kg), THC (50 mg/kg) spontaneous withdrawal 
did not cause a decrease in consumption relative to baseline at 12h [p=.24] or 36h [p=.70] 
abstinence. In this experiment, the vehicle treated mice had continually increasing consumption, 
making comparison between vehicle- and THC (50 mg/kg)-treated mice on test days misleading.  





3.3 Experiment 3a: Acute ZCZ011 does not have anxiolytic or anxiogenic effects. Cannabinoid 
orthosteric ligands, including THC, have anxiolytic properties. To determine possible anxiogenic 
or anxiolytic effects of ZCZ011, behavior was tested in the marble burying, light/dark box, open 
field, and novelty-induced hypophagia tests. Male mice were injected with ZCZ011 (2.5, 5, 10, 
20, or 40 mg/kg) or vehicle 75 min prior to testing in marble burying. Treatment with ZCZ011 
(40 mg/kg) decreased marbles buried [F(5,74)= 14.0, p<.05; Fig. 6A], but also increased 
immobility [F(95,1273)=1.7, p<.05; Fig. 6B], indicating that ZCZ011-suppressed marble 
burying may reflect a broader decrease in activity in the assay. The lowest tested doses of 
ZCZ011 (i.e., 2.5 and 5 mg/kg) did not produce any effects and were excluded from the 
following tests. 
Male and female mice were injected with ZCZ011 (10, 20, or 40 mg/kg, i.p.) or vehicle 
75 min prior to testing in Light/Dark box. ZCZ011 (40 mg/kg) increased time in the dark 
compared to vehicle controls [F(3,44)=2.9, p<.05; Fig. 6C]. Similarly, mice treated with 
ZCZ011 (40 mg/kg) had increased immobility in the light/dark box [F(3,44)= 9.3, p<.05; Fig. 
6D]. In addition, male and female mice were injected with ZCZ011 (10, 20, or 40 mg/kg, i.p.) or 
vehicle 75 min prior to testing in the Open field test. ZCZ011 (10, 20, or 40 mg/kg) did not affect 
time spent in the center of the apparatus [p=.39; Fig. 6E] or time spent immobile [p=.66; Fig. 
6F], but ZCZ011 (40 mg/kg) decreased number of rears [F(3,44)=3.5,p<.05;Fig. 6G]. 
Another group of male and female mice were trained to consume at least 1g of a 
sweetened condensed milk mixture for 3 days prior to testing. Mice were injected with ZCZ011 
(10, 20, or 40 mg/kg, i.p.) or vehicle 75 min prior to testing in either a dim light condition or an 
aversive condition in the presence or absence of ZCZ011, then in the opposite condition after 24 
h. Drug treatment did not change across days. All mice consumed less milk in the aversive 
condition [F(5,290)= 61.36, p<.05; Fig. 6H], and ZCZ011 (10, 20 or 40 mg/kg) did not affect 
volume consumed in the aversive condition [p=.78]. When retrained in the dim condition the 
following day, when no drug was administered, all mice, regardless of treatment or condition 
order, returned to baseline drinking levels [p=.99].  
A separate group of male and female mice was injected with either of the ZCZ011 
enantiomers, referred to here as “ZCZ011A” or “ZCZ011B”, and was tested in open field and 
marble burying tests. Neither compound affected time in the center of the open field [p=.08;Fig. 




7A], time immobile in open field [p=.06;Fig 7B], or rearing (an exploratory behavior) in the 
open field test [p=.79;Fig. 7C]. Neither enantiomer affected marbles buried [p=.20;Fig. 7D], but 
ZCZ011A increased time immobile [F(2,33)=5.9,p<.05;Fig. 7E]. 
 
3.4 Experiment 3b: Somatic signs of THC withdrawal attenuated by ZCZ011. ZCZ011 (10 or 40 
mg/kg) attenuates somatic signs of THC withdrawal (Trexler et al., 2019). To determine whether 
ZCZ011 also attenuates withdrawal-induced changes in marble burying and tail suspension, mice 
were subjected to the rimonabant-precipitated THC withdrawal paradigm and injected with 
ZCZ011 (10 or 40 mg/kg) or vehicle 75 min prior to testing. ZCZ011 (10 or 40 mg/kg) did not 
attenuate THC withdrawal-suppressed marble burying [F(2,42)=12.2,p<.05;Fig. 8A] or 
withdrawal-induced struggling in the tail suspension test [Main effect THC 
[F(1,42)=89.4,p<.05;Fig.8B]. As in Exp. 3.3, ZCZ011 alone (40 mg/kg) increased immobility in 
marble burying [Main effect ZCZ011 [F (2,42)= 7.3,p<.05; Fig. 8C]. Surprisingly, but ZCZ011 
(≥10 mg/kg) increased immobility in mice subjected to precipitated THC withdrawal. 
 To determine ZCZ011 dose-dependent effects on attenuating somatic signs of 
withdrawal, mice were subjected to precipitated THC withdrawal, and injected with ZCZ011 (1, 
3.33, or 10 mg/kg) or vehicle. ZCZ011 (10 mg/kg) reduced both paw tremors 
[F(4,32)=6.8,p<.05;Fig.8D] and head twitches [F(4,32)=4.5,p<.05;Fig.8E]. Posts hoc analyses 
revealed that ZCZ011 (3.33 mg/kg) attenuated head twitches but had no effect on paw tremors.  
 The ability of the two enantiomers of ZCZ011, i.e., ZCZ011A and ZCZ011B, to attenuate 
precipitated THC withdrawal was evaluated. Mice were subjected with precipitated THC 
withdrawal and treated with ZCZ011A or ZCZ011B (0.55, 1.66, or 5 mg/kg) or vehicle 75 min 
prior to testing. Either ZCZ011A or ZCZ011B (5 mg/kg) attenuated paw tremors 
[F(4,35)=16.7,p<.05;Fig.8F] and head twitches [F(4,35)=10.8,p<.05;Fig.8G]. Neither ZCZ011A 
nor ZCZ011B (0.55 or 1.66 mg/kg) affected paw tremors [p=.28;Fig. 8H] or head twitches 
[p=.20;Fig. 8I].  
4. Discussion 
 The current project was designed to evaluate the acute and chronic effects of the synthetic 
cannabinoid AB-FUBINACA. It also evaluated the development of tolerance to and withdrawal 
from AB-FUBINACA. Additionally, sweetened condensed milk consumption was evaluated as a 




potential new assay of spontaneous THC withdrawal. Finally, the acute anxiolytic effects of 
ZCZ011 and its enantiomers was probed and ZCZ011 and its enantiomers were further evaluated 
as a method of attenuating precipitated THC withdrawal. 
 AB-FUBINACA produced classic cannabinoid effects, including catalepsy, anti-
nociception, hypothermia, and hypolocomotion. Surprisingly, AB-FUBINACA has a 
significantly shorter timecourse than THC and previous generation synthetic cannabinoids. 
While a rapid onset, similar to the one observed here, has been reported previously, the tetrad 
effects in the present study abated more quickly than previously reported (Banister, Moir, et al., 
2015; Kevin et al., 2017). It is plausible that the differences in observed effect timecourse and 
magnitude are due to a species difference, as the previous studies were carried out in rats. 
Regardless, the rapid onset and relatively short timecourse are similar to those seen with other 
third-generation synthetic cannabinoids, including AB-CHMINACA delivered via inhalation 
(Lefever et al., 2017). A likely mechanism for the relatively quick recovery from these 
compounds is rapid metabolism. Previous studies have demonstrated that synthetic cannabinoids 
tend to be rapidly metabolized, and that more or less potent metabolites remain in the organism 
interacting with cannabinoid receptors (Brents et al., 2012). It has been further suggested that an 
alternate route of administration (e.g., inhalation) may be a better model of synthetic cannabinoid 
use because these compounds are generally administered in vapor (Lefever et al., 2017), which 
most closely resembles intravenous administration with regard to speed of delivery to brain. 
Moreover, the rapid timecourse of new generation drugs is even further accelerated in an inhaled 
aerosol model (Lefever et al., 2017). Regardless, the relatively short timecourse of AB-
FUBINACA reported here is novel and evident following intraperitoneal administration.   
 The lack of tolerance to AB-FUBINACA in the current experiments is in some ways 
surprising, as the dosing regimen is adequate to produce tolerance to both THC and other 
synthetic cannabinoids, like WIN55-212 and JWH-018 (Aceto et al., 2001; Lichtman, Fisher, & 
Martin, 2001; Schlosburg et al., 2009; Trexler et al., 2018). Additionally, AB-FUBINACA is a 
full CB1 agonist with higher potency than THC (Hess et al., 2016; Wiley et al., 2015). Thus, we 
expected tolerance to develop at the same rate, or perhaps even earlier, than with THC. However, 
the rapid timecourse of AB-FUBINACA metabolism may render the current dosing paradigm 
ineffective. Thus, it is plausible that, for tolerance to fully develop, mice must be dosed more 




frequently, or perhaps ideally administered continuously, for example via osmotic minipump. 
But, such an approach has limited construct validity and does not reflect patterns of human 
cannabinoid self-administration. Regardless, the small effect of precipitated AB-FUBINACA 
withdrawal is not surprising, given the observed lack of tolerance in the tetrad battery. It was also 
expected that, given its relatively higher potency, AB-FUBINACA withdrawal would be of the 
same or perhaps larger magnitude than that of THC, but the observed withdrawal effects, while 
statistically significant, were relatively minor. This issue may also be resolved by adjusting the 
dosing regimen as outlined above, or perhaps other behavioral assays will reveal subtleties in 
AB-FUBINACA withdrawal that were not detectable with the present assays. 
 Generally, AB-FUBINACA exhibited cannabimimetic effects in the tetrad battery of 
assays, but has a much faster time course. To further explore the effects of AB-FUBINACA, 
future studies should include components evaluating brain, plasma, or urine analysis for 
metabolites of the drug over time. I anticipate that AB-FUBINACA is rapidly metabolized in 
vivo, and that patterns of brain levels will mirror those of the behavioral assays reported on here. 
Additional studies that challenge the effects of AB-FUBINACA, for example with the CB1 
inverse agonist rimonabant, will also be useful in determining whether all of the effects observed 
were CB1 mediated, or if AB-FUBINACA is acting, at least in part, through cannabinoid 
receptor independent mechanisms.  
 Due to the small effect of precipitated AB-FUBINACA withdrawal, THC was used to 
pilot the possible effects of cannabinoid withdrawal on sweetened condensed milk consumption. 
We evaluated spontaneous THC withdrawal effects on sweetened condensed milk consumption, 
a common anhedonia model. We chose a spontaneous withdrawal paradigm, because pilot data 
(Fig 5A) indicated that rimonabant, per se, suppresses drinking. In the present study, 
spontaneous THC withdrawal was evaluated 36 h after the final THC injection. This 36 h 
timepoint was selected because we have previously reported “peak” withdrawal signs at 36 h 
THC abstinence (Trexler et al., 2018). I hypothesized that mice would exhibit decreased 
sweetened condensed milk consumption during spontaneous withdrawal, but this effect was not 
observed. Given the lack of an effect of THC withdrawal, we chose not to test spontaneous AB-
FUBINACA withdrawal in this model. Because somatic signs of precipitated AB-FUBINACA 
withdrawal (i.e., Exp 2a) were of surprisingly small magnitude, and that effects of spontaneous 




withdrawal are typically of a smaller magnitude than precipitated withdrawal models (Aceto et 
al., 2001;Trexler, Eckard, & Kinsey, 2019; Trexler et al., 2018), we concluded that spontaneous 
AB-FUBINACA withdrawal effects on sweetened condensed milk consumption are unlikely to 
be observed. 
In addition to measuring feeding behavior, sweetened milk drinking was chosen in this 
study because of its use in evaluating depressive-like effects (i.e., anhedonia), which humans 
frequently report as a symptom of cannabis withdrawal (American Psychiatric Association, 
2013). Because of the differences in type of symptomology (i.e, somatic symptoms versus 
emotionality-related symptoms), it is plausible that the onset of different behavioral changes 
occur at different times. For example, we have previously reported that both precipitated and 
spontaneous THC withdrawal increase struggling in the tail suspension test (Trexler et al., 2018). 
Coincident with spontaneous somatic withdrawal signs, the increase in struggling is evident at 36 
h abstinence. Thus, although we did not observe altered drinking at 12 or 36 h abstinence, 
expending the number of time points of sampling may reveal a withdrawal time course in this 
assay that differs from other models. Another approach would be to increase THC dosing, 
perhaps to 50 mg/kg twice daily, with the goal of increasing withdrawal effects. Although we 
have not observed differences between 10 and 50 mg/kg THC in somatic signs of withdrawal or 
tail suspension tests (Trexler et al., 2018), it is plausible that feeding is sensitive to such 
differences in dosing. 
 Acute ZCZ011 was evaluated in several anxiety-related assays because increased activity 
of the endocannabinoid system has anxiolytic effects (Kinsey, O’Neal, Long, Cravatt, & 
Lichtman, 2011; Moreira, Grieb, & Lutz, 2009). ZCZ011 decreased marble burying and 
decreased rearing in the open field test, which would typically be interpreted as an anxiolytic 
drug profile. In the light/dark box test, however, ZCZ011 increased time spent in the dark, which 
would typically be interpreted as an anxiogenic effect. But, the same dose of ZCZ011 (40 mg/kg) 
also elicited locomotor effects in both the marble burying and light/dark box tests, indicating that 
the decrease in marbles buried and increased time in the dark were likely due to sedative effects. 
This effect contrasts with findings showing the same dose of ZCZ011 does not produce 
locomotor suppression the spontaneous locomotor test (Ignatowska-Jankowska et al., 2015; 
Trexler et al., 2019). The light/dark box test relies on creating a conflict paradigm to evaluate 




anxiety-like behavior (Crawley, 2007) and the marble burying test also been implicated as a 
stress-inducing paradigm (Abraham et al., 2018), so it is plausible that the locomotor effects of 
ZCZ011 are only observed in stressful or aversive conditions, which would not include the 
apparatus used in a spontaneous locomotor assessment. Thus, the assay dependent locomotor 
effects observed may be compounded by stress responsiveness.  
 Both enantiomers of ZCZ011, ZCZ011A and ZCZ011B, were evaluated independently in 
marble burying and open field assays. ZCZ011A caused decreased locomotion in the marble 
burying task, but did not cause a statistically significant reduction in number of marbles buried. 
We found no effects of either enantiomer in open field, which is consistent with the lack of effect 
of ZCZ011 in open field. The locomotor deficits observed in the marble burying and light/dark 
box tests are the result of ZCZ011A, rather than ZCZ011B, as evidenced by the locomotor 
deficit associated with ZCZ011A in the marble burying test. Future studies evaluating dose 
dependent effects of the individual enantiomers and evaluation in the light/dark box assay are 
needed to determine relative contributions of each enantiomer.  
Precipitated THC withdrawal was challenged with ZCZ011 in the marble burying and tail 
suspension tests. Interestingly, precipitated withdrawal-depressed marble burying and increased 
tail suspension struggling were not attenuated by ZCZ011 (10 and 40 mg/kg), which is similar to 
previous findings using the MAGL inhibitor JZL184 (Trexler et al., 2018), which increases brain 
levels of 2-AG by preventing its catabolism. Both ZCZ011 and JZL184 attenuate both 
precipitated and spontaneous somatic signs of withdrawal, but neither drug reverses withdrawal-
depressed marble burying or withdrawal-induced increases in struggling in the tail suspension 
test. Plasma levels of the stress hormone corticosterone increase during THC withdrawal, and the 
endocannabinoid system and stress circuitry are closely related (Hill & Gorzalka, 2005; Oliva et 
al., 2004; Patel, Roelke, Rademacher, & Hillard, 2005; Trexler et al., 2018). Thus, the decrease 
in marble burying and increase in struggling during THC withdrawal may be related to altered 
regulation of the hypothalamic-pituitary-adrenal (HPA) axis stress circuit caused by repeated 
CB1 activation. Interestingly, these effects are not attenuated by administration of a 
glucocorticoid antagonist, mifepristone, or a β-adrenergic antagonist, propranolol, indicating the 
effect is likely not mediated through those mechanisms (Trexler et al., 2018). Thus, future 
studies should target corticotrophin releasing factor as a stress mechanism that mediates the 
emotionality-related behavioral effects of cannabinoid withdrawal.  




ZCZ011 attenuated somatic signs of THC withdrawal in a dose dependent manner. The 
lowest dose tested, 1 mg/kg, did not attenuate paw tremors or head twitches, and the moderate 
dose, 3 mg/kg, attenuated head twitches, but not paw tremors, and the highest dose tested, 10 
mg/kg, attenuated both paw tremors and head twitches, as previously published (Trexler et al., 
2019). It is noteworthy that, no locomotor effects of 10 mg/kg ZCZ011 are observed in any 
assays, which rules out possible sedative confounds. CB1 positive allosteric modulation is a 
relatively new area, but several PAMs have already shown demonstrated their anti-nociceptive, 
anti-inflammatory, and gastroprotective properties (Ignatowska-Jankowska et al., 2015; Slivicki 
et al., 2017; Trexler et al., 2019), so this approach has been fruitful, albeit using different 
endogenous target receptor systems. Further, the finding that either enantiomer of ZCZ011 
attenuates somatic signs of withdrawal is promising. Moreover, ZCZ011B not only attenuates 
withdrawal, but does so with no locomotor effects of its own. Taken together, the present data 
indicate that ZCZ011B, or a novel compound with similar properties, shows early promise as an 
option for development as a therapeutic agent to treat cannabis use disorder.  
 
5. Conclusion 
 The present studies revealed that AB-FUBINACA, a third-generation synthetic 
cannabinoid, has cannabimimetic effects that abate much more rapidly than the traditional 
phytocannabinoid, THC. Future studies into its metabolism will help to further understand the 
differences between AB-FUBINACA and THC. As human use of synthetic cannabinoids 
continues it will be increasingly important to use the information gained from experimental study 
to inform treatments for synthetic cannabinoids. Though spontaneous THC withdrawal is reliably 
observed in somatic and tail suspension models, it was undetectable in an anhedonia model. The 
exploration of additional timepoints may reveal that in the anhedonia model, THC withdrawal 
peaks at a different time. Finally, ZCZ011 has few acute effects on its own, and the effects it 
does have are likely driven by sedative effects, which appear to be caused entirely by one 
enantiomer, ZCZ011A. Further, ZCZ011 and each of its enantiomers attenuate THC withdrawal 
in a somatic model at doses that do not produce sedative effects. ZCZ011B may also be a 
therapeutic agent due to its ability to attenuate withdrawal and its lack of acute locomotor effects. 
Regardless of the individual contributions of either enantiomer, these data provide proof-of-




concept that CB1 positive allosteric modulation is a viable strategy for reducing cannabis use 
disorder.  
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Figure 3. AB-FUBINACA has short-acting cannabinoid effects. Male and female mice were 
treated with AB-FUBINACA (0.1-3 mg/kg, i.p.) 30 min prior to testing in the tetrad battery. AB-
FUBINACA induced catalepsy (A) antinociception (B), hypothermia (C), and hypolocomotion 
(D), consistent with established cannabinoid effects. A second group of male and female mice 
was injected with AB-FUBINACA (3 mg/kg, i.p.) or THC (50 mg/kg) and tested repeatedly in a 
modified tetrad battery. The effects of AB-FUBINACA abated more quickly than the effects of 
THC in catalepsy (E), antinociception (F), and hypothermia (G). Data represent mean ± SEM 










Figure 4. Chronic effects of AB-FUBINACA. Mice were treated with twice daily with AB-
FUBINACA (3 mg/kg, i.p.) or vehicle for 5 days. Mice were assessed in a modified tetrad 
battery every morning approximately 30 min after injections. Mice treated with AB-FUBINACA 
did not develop tolerance to its effects in catalepsy (A), tail immersion (B), or body temperature 




(C). On the 6th day, mice were baselined, then injected with THC (50 mg/k, i.p.) to evaluate 
cross-tolerance. Mice treated with AB-FUBINACA showed no cross tolerance to THC in 
catalepsy (D), antinociception (E), or hypothermia (F). To evaluate precipitated withdrawal from 
AB-FUBINACA, separate groups of mice were treated with AB-FUBINACA (1 or 3 mg/kg, i.p.) 
twice daily for 6 days. On the 6th day, mice were injected with rimonabant and then evaluated for 
somatic signs of withdrawal. AB-FUBINACA (1 or 3 mg/kg) increased paw tremors (G & I) and 
head twitches (H & J). Data represent mean ± SEM (n=8-10 [4-5m/4-5f] /group); *p<.05 v. 
























Figure 5. Spontaneous THC withdrawal had no effect on feeding. Mice were treated twice daily 
with JWH-018 (1 mg/kg) or vehicle for 6 days and were then subjected to precipitated 
withdrawal. Rimonabant decreased drinking in both JWH-018 and vehicle treated mice (A). 
Mice were treated with twice daily with THC (10 mg/kg, i.p.) or vehicle for 5 days. Mice were 
assessed an anhedonia assay 12 h and 36 h after the final THC or vehicle injection  
(B). No effect of spontaneous THC (10 mg/kg) withdrawal was observed. Similarly, mice treated 
for 5 days with THC (50 mg/kg, i.p.) or vehicle did not show spontaneous withdrawal at 12h or 
36h (C). Data represent mean ± SEM (n=8 [4m/4f]/group) *p<.05 v. vehicle control; #p<.05 v. 


















Figure 6. Acute ZCZ011 decreased marble burying and increased immobility in a subset of tests. 
Separate groups of mice were treated with acute ZCZ011 (2.5-40 mg/kg, i.p.) or vehicle 75 min 
prior to testing. Mice treated with ZCZ011 (40 mg/kg) buried fewer marbles (A) and spent more 
time immobile in marble burying (B). Mice treated with ZCZ011 (40 mg/kg) spent more time in 
the dark (C) and more time immobile in the light/dark box test (D). Mice treated with ZCZ011 
(40 mg/kg) did not differ in time spent in the center of the open field (E) or time spent immobile 
(F) but reared less (G). ZCZ011 did not affect amount consumed in novelty-induced hypophagia 
(H). Data represent mean ± SEM (n=12-16[6-8m/6-8f]/group); *p<.05 v. vehicle or baseline. 
 





Figure 7. Acute effects of ZCZ011 enantiomers. Mice were treated with either acute ZCZ011A 
(20 mg/kg, i.p.), ZCZ011B (20 mg/kg, i.p.) or vehicle 75 min prior to testing .Neither ZCZ011A 
nor ZCZ011B affected time in the center of the open field (A), time immobile during open field 
(B), or rearing (C). Neither ZCZ011A nor ZCZ011B affected marbled buried (D), but ZCZ011A 
increased time spent immobile in marble burying (E). Data represent mean ± SEM 


















Figure 8. ZCZ011 attenuates somatic signs of precipitated THC withdrawal. Separate groups of 
mice were treated with THC (10 mg/kg, i.p.) or vehicle twice daily for 6 days. On the 6th day, 




mice were injected with ZCZ011 (1-40 mg/kg) or vehicle, then injected with rimonabant and 
then evaluated in marble burying and tail suspension or somatic signs of withdrawal. ZCZ011 
(10 or 40 mg/kg) did not attenuate withdrawal-induced changes in marble burying (A) or tail 
suspension test (C). ZCZ011 (10 or 40 mg/kg increased immobility in mice subjected to 
withdrawal in marble burying (B). ZCZ011 (10 mg/kg) attenuated paw tremors (D) and head 
twitches (E). In a second set of experiments, mice were treated on the 6th day with ZCZ011A 
(0.55-5 mg/kg, i.p.), ZCZ011B (0.55-5 mg/kg, i.p.) or vehicle, then injected with rimonabant and 
evaluated for somatic signs of THC withdrawal. Both ZCZ011A (5 mg/kg) and ZCZ011B (5 
mg/kg) attenuated paw tremors (F) and head twitches (G). Neither ZCZ011A (0.55 or 1.66 
mg/kg) nor ZCZ011B (0.55 or 1.6 mg/kg) attenuated paw tremors (H) or head twitches (I). Data 








Appendix A. Analysis of covariance (ANCOVA) for experiments 2, 3a, and 3b. 
 To standardize drinking across days in the anhedonia assays in experiment 2, an analysis 
of covariance (ANCOVA) was conducted using baseline as a covariate. Even when baseline 
consumption was considered, there was no difference in consumption between THC (10 mg/kg) 
and vehicle treated mice at 12h [p=.80] or 36h [p=.76]. When baseline was used as a covariate 
for THC (50 mg/kg) withdrawal, again, at 12h there was no difference in consumption [p=.07]. 
Interestingly, THC (50 mg/kg) withdrawal caused a significant decrease in consumption at 36h 
when analyzed using ANCOVA [F(1,11)=9.07, p<.05]. 
 I speculated that the decrease in marbles buried and increase in time spent in the dark 
observed in experiment 3a following ZCZ011 administration was due to increased immobility. 
To determine whether immobility affected marbles buried and time spent in the dark during 
light/dark box, separate ANCOVAs were done using time immobile as the covariate. Indeed, 
when analyzed with ANCOVA, the initial decrease in marbles buried is no longer significant 
[p=.17], nor is the increase in time spent in the dark during the light/dark box test [p=.08]. This 
indicates that the observed changes were related to increased immobility.  
 Finally, in experiment 3b, I speculated that the decrease in marbles buried in ZCZ011 
treated mice was due to increased immobility. Again, an ANCOVA was done to determine 
whether this was the case and again, the decrease in marbles buried was no longer significant 
















Appendix B. Table of post hoc analyses.  The post hoc analyses completed for the present experiments are listed in the 
table below. Bold indicates significance. 
  
  
Experiment 1: AB-FUBINACA induces classic cannabinoid effects         
Acute tetrad - compared via Dunnett's against 
vehicle control 




difference   
Catalepsy 0.1 -0.234 6.331   
  1 -0.234 6.331   
  2 1.952 6.553   
  3 11.401 6.838   
       
 Tail immersion 0.1 -0.679 3.94   
  1 2.926 3.94   
  2 3.698 3.94   
  3 6.349 3.94   
       
 Body Temperature 0.1 -0.2 -1.92   
  1 -.537 -1.92   
  2 -4.15 -1.92   
  3 -5.75 -1.92   
       
 Locomotor 0.1 12.988 73.408   
  1 39.338 73.408   
  2 104.05 73.408   
  3 163.263 73.408   
       
Repeated dosing tetrad - compared via t-test 
against vehicle with Bonferroni correction 
(significant if p< 0.01); df:14 
 Group t value p value   
Catalepsy Day 1 1.296 0.2166   
 Day 2 7.164 <.0001   
  Day 3 2.424 0.0295   
  Day 4 4.105 0.0011   
  Day 5 3.514 0.0034   
       
 Tail immersion Day 1 2.986 0.0098   
  Day 2 2.146 0.0499   
  Day 3 1.998 0.0655   
  Day 4 3.08 0.0081   




  Day 5 2.292 0.0379   
       
 Body Temperature Day 1 -10.413 <.0001   
  Day 2 -12.6 <.0001   
  Day 3 -3.98 0.0014   
  Day 4 -3.297 0.0053   
  Day 5 -4.276 0.0008   
       
AB-FUBINACA (3 mg/kg) precipitated 
withdrawal - compared via Bonferroni (significant 
if p< 0.0167) 





difference p value  
Paw tremors Vehicle v. AB-F 0.625 3.839 0.6751  
  Vehicle v. AB-F/Rim -5.518 3.974 0.0017  
  AB-F v. AB-F/Rim -6.143 3.974 0.0006  
       
 Head twitches Vehicle v. AB-F 0.25 2.652 .8.14  
  Vehicle v. AB-F/Rim -2.464 2.652 0.0248  
  AB-F v. AB-F/Rim -2.714 2.652 0.0146  
       
AB-FUBINACA and THC tetrad timecourse - 
compared via Dunnett against baseline 










 Catalepsy 0 min 0 18.715 0 15.823 
  15 min 36.881 18.715 13.755 15.823 
  30 min 25.327 18.715 16.585 15.823 
  1h 14.046 18.715 17.558 15.823 
  2h 0.748 18.715 14.134 15.823 
  4h 0.564 18.715 8.129 15.823 
  8h 0 18.715 0 15.823 
  12h 0 18.715 0.851 15.823 
  24h 0 18.715 0 15.823 
  48h 0 18.715 0 15.823 
       
 Tail immersion 5 min 1.357 2.897 0.643 3.082 
  20 min 5.279 2.897 5.248 3.082 
  35 min 6.731 2.897 6.309 3.082 




  1h 2.865 2.897 5.978 3.082 
  2h 1.769 2.897 7.365 3.082 
  4h 0.549 2.897 8.053 3.082 
  8h 0.786 2.897 5.698 3.082 
  12h 0.226 2.897 3.569 3.082 
  24h 0.63 2.897 -0.153 3.082 
  48h 0.042 2.897 -0.314 3.082 
       
 Body Temperature 10 min -2.013 1.751 -1.088 1.185 
  25 min -6.913 1.751 -5.675 1.185 
  40 min -6.775 1.751 -6.45 1.185 
  1h -5.163 1.751 -6.838 1.185 
  2h -2.125 1.751 -7.137 1.185 
  4h -0.587 1.751 -6.213 1.185 
  8h -0.188 1.751 -3.913 1.185 
  12h 0.188 1.751 -2.45 1.185 
  24h -0.35 1.751 -0.35 1.185 
  48h -0.125 1.751 -0.1 1.185 
       
Experiment 2: Spontaneous THC withdrawal does not affect feeding      
JWH-018 spontaneous withdrawal - compared via 
ANOVA with Bonferroni correction (significant if 
p<0.005); df:1,28 
 Timepoint f value p value   
JWH-018 main effects Training day 1 0.088 0.7685   
 Training day 2 0.507 0.4822   
  Training day 3 0 0.9994   
  Dosing day 1 279.336 <.0001   
  Dosing day 2 52.732 <.0001   
  Dosing day 3 19.012 0.0002   
  Dosing day 4 7.002 0.0132   
  Dosing day 5 2.69 0.1122   
  Test day 0.057 0.8137   
  Reversal day 8.114 0.0081   
       
 
Rimonabant main 
effects Training day 1 0.016 0.9004   
  Training day 2 0.082 0.7766   




  Training day 3 0.195 0.6626   
  Dosing day 1 0.463 0.5018   
  Dosing day 2 0.31 0.5823   
  Dosing day 3 1.023 0.3205   
  Dosing day 4 0.01 0.9204   
  Dosing day 5 1.189 0.2848   
  Test day 95.051 <.0001   
  Reversal day 0.358 0.5545   
       
 Interactions Training day 1 2.221 0.1474   
  Training day 2 0.48 0.494   
  Training day 3 0.686 0.4146   
  Dosing day 1 0.554 0.4629   
  Dosing day 2 5.39 0.0277   
  Dosing day 3 0.011 0.9188   
  Dosing day 4 0.269 0.6081   
  Dosing day 5 0.052 0.537   
  Test day 0.152 0.6999   
  Reversal day 0.401 0.5319   
       
THC spontaneous withdrawal - compared via t 
test with Bonferroni correction (significant if 
p<0.005); df:14 
 Timepoint t value p value   
THC (10 mg/kg) Training day 1 0.638 0.5337   
 Training day 2 0.831 0.199   
  Training day 3 0.652 0.5252   
  Dosing day 1 2.693 0.0184   
  Dosing day 2 2.408 0.0304   
  Dosing day 3 2.855 0.0127   
  Dosing day 4 2.825 0.0135   
  Dosing day 5 1.386 0.1891   
  12 h abstinence 0.485 0.652   
  36h abstinence 0.903 0.3817   
       
  Timepoint t value p value   
 THC (50 mg/kg) Training day 1 -0.168 0.8693   




  Training day 2 -0.547 0.5929   
  Training day 3 -1.378 0.1915   
  Dosing day 1 5.905 <.0001   
  Dosing day 2 -3.196 0.0065   
  Dosing day 3 -4.134 0.001   
  Dosing day 4 -3.67 0.0025   
  Dosing day 5 -5.355 0.0001   
  12 h abstinence 0.115 0.9099   
  36h abstinence -0.159 0.8758   
       
3.3 Experiment 3a: Acute ZCZ011 does not have anxiolytic or anxiogenic effects     
ZCZ011 Marble burying dose response - 
compared via Dunnett against vehicle 




Difference   
Marble burying 2.5 4.57 4.808   
  5 3.07 5.276   
  10 1.373 4.593   
  20 -3.192 4.593   
  40 -10.513 4.808   
       
 Immobility 2.5 -0.636 5.618   
  5 0.849 5.815   
  10 0.589 5.308   
  20 4.921 5.308   
  40 21.009 5.308   
       
ZCZ011 Light/Dark Box dose response - 
compared via Dunnett against vehicle 




Difference   
Time in dark 10 9.3 39.072   
  20 21.342 39.072   
  40 45.025 39.072   
       
 Immobility 10 3.05 37.252   
  20 25.675 37.252   
  40 71.925 37.252   
       




ZCZ011 Open field dose response - compared via 
Dunnett against vehicle 




Difference   
Number of rears 10 1.417 12.784   
  20 -3.5 12.784   
  40 -13.917 12.784   
       
ZCZ011 enantiomer marble burying immobility - 
compared via Dunnett against 1 min 
  ZCZ011 A ZCZ011 B 









 2 2.15 16.016 2.925 9.115 
  3 0.7 16.016 0.825 9.115 
  4 3.763 16.016 4.7 9.115 
  5 4.15 16.016 2.175 9.115 
  6 7.35 16.016 4.725 9.115 
  7 8.138 16.016 1.688 9.115 
  8 11.213 16.016 4.2 9.115 
  9 10.975 16.016 3.65 9.115 
  10 14.363 16.016 4.388 9.115 
  11 13.488 16.016 4.725 9.115 
  12 18.988 16.016 6.188 9.115 
  13 11.387 16.016 4.95 9.115 
  14 27.775 16.016 8.262 9.115 
  15 32.25 16.016 4.675 9.115 
  16 30.45 16.016 3.15 9.115 
  17 22.438 16.016 4.463 9.115 
  18 33.2 16.016 9.5 9.115 
  19 35.425 16.016 11.35 9.115 
  20 44.575 16.016 14.488 9.115 
       
3.4 Experiment 3b: Somatic signs of THC withdrawal attenuated by 
ZCZ011      
THC precipitated withdrawal with ZCZ011 
attenuation in marble burying - compared via 
 Comparison t value p value   
Marble burying Vehicle v. THC 3.466 0.0038   
 Vehicle v. THC+ZCZ 10 6.311 <.0001   




planned t tests with Bonferroni correction 
(significant if p<0.0125); df:14  Vehicle v. THC+ZCZ 40 0.858 0.4051   
       
THC precipitated withdrawal with ZCZ011 
attenuation in somatic signs - compared via  





difference p value  
Paw tremors Vehicle v. THC -46.857 32.277 0.0001  
 Vehicle v. THC+ZCZ 1 -36.696 31.252 0.0012  
  Vehicle v. THC+ZCZ 3.33 37.286 32.277 0.015  
  Vehicle v. THC+ZCZ 10 -12.696 31.252 0.2296  
  THC v. THC+ZCZ 1 10.161 31.252 0.3343  
  THC v. THC+ZCZ 3.33 9.571 32.277 0.378  
  THC v. THC+ZCZ 10 34.161 31.252 0.0024  
  
THC+ZCZ 1 v. THC+ZCZ 
3.33 -0.589 31.252 0.975  
  THC+ZCZ 1 v. THC+ZCZ 10 24 30.192 0.0226  
  
THC+ZCZ 3.33 v. THC+ZCZ 
10 24.589 31.252 0.0239  
       
 Head twitches Vehicle v. THC -7.286 5.652 0.0005  
  Vehicle v. THC+ZCZ 1 -5.625 5.473 0.004  
  Vehicle v. THC+ZCZ 3.33 -3.286 5.652 0.0892  
  Vehicle v. THC+ZCZ 10 -2.875 5.473 0.123  
  THC v. THC+ZCZ 1 1.661 5.473 0.3671  
  THC v. THC+ZCZ 3.33 4 5.652 0.0406  
  THC v. THC+ZCZ 10 4.411 5.473 0.0209  
  
THC+ZCZ 1 v. THC+ZCZ 
3.33 2.339 5.473 0.2067  
  THC+ZCZ 1 v. THC+ZCZ 10 2.75 5.287 0.1267  
  
THC+ZCZ 3.33 v. THC+ZCZ 
10 0.411 5.473 0.8824  
       
THC precipitated withdrawal with ZCZ011 
enantiomer (5 mg/kg only) attenuation in somatic 






difference p value  
Paw tremors Vehicle v. THC -38.625 16.135 <.0001  
 Vehicle v. THC+ZCZ 10 -1.875 16.135 0.7298  
 Vehicle v. THC+ZCZ A -10.375 16.135 0.0622  
  Vehicle v. THC+ZCZ B -8.375 16.135 0.1289  




  THC v. THC+ZCZ 10 36.75 16.135 <.0001  
  THC v. THC+ZCZ A 28.25 16.135 <.0001  
  THC v. THC+ZCZ B 30.25 16.135 <.0001  
  THC+ZCZ 10 v. THC+ZCZ A -8.5 16.135 0.1235  
  THC+ZCZ 10 v. THC+ZCZ B -6.5 16.135 0.2355  
  THC+ZCZ A v. THC+ZCZ B 2 16.135 0.7126  
       
 Head twitches Vehicle v. THC -5.375 2.854 <.0001  
  Vehicle v. THC+ZCZ 10 -0.125 2.854 0.8963  
  Vehicle v. THC+ZCZ A -0.875 2.854 0.3645  
  Vehicle v. THC+ZCZ B -1.625 2.854 0.0968  
  THC v. THC+ZCZ 10 5.25 2.854 <.0001  
  THC v. THC+ZCZ A 4.5 2.854 <.0001  
  THC v. THC+ZCZ B 3.75 2.854 0.0004  
  THC+ZCZ 10 v. THC+ZCZ A -0.75 2.854 0.4363  
  THC+ZCZ 10 v. THC+ZCZ B -1.5 2.854 0.1243  
    THC+ZCZ A v. THC+ZCZ B -0.75 2.854 0.4363  
 
